AGENUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.28 USD | -14.44% |
|
-3.97% | -13.76% |
| Jun. 28 | Sector Update: Health Care Stocks Edge Higher in Afternoon Trading | MT |
| Jun. 28 | Agenus Shares Rise After Trial Shows Tumor Reductions in Colon Cancer Patients | MT |
Financials (USD)
| Sales 2024 * | 206M | Sales 2025 * | 183M | Capitalization | 300M |
|---|---|---|---|---|---|
| Net income 2024 * | -185M | Net income 2025 * | -230M | EV / Sales 2024 * | 1.45 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.63 x |
| P/E ratio 2024 * |
-1.6
x | P/E ratio 2025 * |
-1.65
x | Employees | 389 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on Agenus Inc.
More recommendations
More press releases
| 1 day | -14.44% | ||
| 1 week | -3.97% | ||
| Current month | -14.75% | ||
| 1 month | -8.99% | ||
| 3 months | +39.45% | ||
| 6 months | -10.77% | ||
| Current year | -13.76% |
1 week
13.75
17.99
1 month
12.3419.69
Current year
4.7819.69
1 year
4.7838.60
3 years
4.78135.80
5 years
4.78135.80
10 years
4.78203.20
| Managers | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director of Finance/CFO | 58 | 95-12-31 | |
Craig Winter
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director/Board Member | 66 | 16-05-16 | |
Susan Hirsch
BRD | Director/Board Member | 71 | 20-10-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.15% | 26 M€ | -6.65% | - | |
| 0.01% | 775 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 14.28 | -14.44% | 674,637 |
| 24-07-01 | 16.69 | -0.36% | 776,641 |
| 24-06-28 | 16.75 | +18.63% | 1,520,955 |
| 24-06-27 | 14.12 | -0.63% | 288,124 |
| 24-06-26 | 14.21 | -4.44% | 419,282 |
Delayed Quote Nasdaq, July 02, 2024 at 04:00 pm EDT
More quotes
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.28
USD
Average target price
44.25
USD
Spread / Average Target
+209.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.76% | 300M | |
| +17.72% | 44.87B | |
| -10.33% | 37.8B | |
| +41.31% | 37.61B | |
| +29.36% | 31.32B | |
| -8.44% | 27.4B | |
| +12.45% | 26.32B | |
| +44.19% | 14.07B | |
| +31.93% | 12.5B | |
| -7.67% | 11.23B |
- Stock Market
- Equities
- AGEN Stock
